Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BMRN with free AI briefings, catalyst countdowns, and dilution alerts.

BMRN · BIOMARIN PHARMACEUTICAL INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash on Hand
CF+ Cash Runway
Follow BMRN by email Get an email when BMRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BMRN, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-02-28 VOXZOGO children with achondroplasia NDA 66% ±20% by Apr 16
2027-05-30 VOXZOGO hypochondroplasia (HCH) NDA 66% –

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What BMRN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sapropterin
FDA approved Dec 2007 · Kuvan
GTP Cyclohydrolase Deficiency Phase 1/2 · NCT01425528 Completed
Pegvaliase-Pqpz
FDA approved May 2018 · Palynziq
Phenylketonuria Phase 4 · NCT07477691 Recruiting
Vosoritide
FDA approved Nov 2021 · Voxzogo
Achondroplasia Phase 3 · NCT03424018 Active not recruiting
Cerliponase Alfa
FDA approved Apr 2017 · Brineura
Jansky-Bielschowsky Disease Phase 2 · NCT02678689 Completed
Elosulfase Alfa
FDA approved Feb 2014 · Vimizim
Mucopolysaccharidosis IV A N/A · NCT03204370 Completed
RDD to Palynziq Phenylketonuria Phase 4 · NCT06780332 Completed
Vosoritide Injection [Voxzogo] Achondroplasia Phase 2/3 · NCT07441876 Recruiting
Valoctocogene Roxaparvovec Hemophilia A Phase 3 · NCT06224907 Active not recruiting
INZ-701 Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency Phase 3 · NCT06046820 Terminated
Control Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency Phase 3 · NCT06046820 Terminated
BMN 333 Achondroplasia Phase 2/3 · NCT07441876 Recruiting
BMN 307 Phenylketonuria (PKU) Phase 1/2 · NCT04480567 Active not recruiting
BMN 351 Duchenne Muscular Dystrophy Phase 1/2 · NCT06280209 Active not recruiting
Human Growth Hormone Idiopathic Short Stature Phase 2 · NCT06382155 Recruiting
BMN 349 Alpha 1-Antitrypsin Deficiency Phase 1 · NCT06738017 Active not recruiting
L-Ascorbate Claudication, Intermittent Phase 1 · NCT04800692 Active not recruiting

Also used in these trials (approved or third-party drugs, not BMRN's own candidates): Methotrexate, L-Arginine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BMRN holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMRN files for a raise →

👥 Who Owns BMRN

Insiders 0.5% Institutions (784 holders) 99.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 19,373,309 10.00% 2026-10-31
Vanguard Capital Management Institution (13G, 5%+) 10,113,219 5.22% 2026-03-31
Alexander Hardy
Chief Executive Officer, Director · +89,200 options
Insider 214,635 0.11% 2026-03-17
Richard A Meier
Director
Insider 126,926 0.07% 2025-12-31
Brian Mueller
EVP, Chief Financial Officer · +44,600 options
Insider 123,314 0.06% 2026-03-17
Charles Greg Guyer
EVP, Chief Technical Officer · +35,680 options
Insider 84,140 0.04% 2026-03-17
George Eric Davis
EVP, Chief Legal Officer · +34,690 options
Insider 61,003 0.03% 2026-09-02
Robert J. Hombach
Director
Insider 49,360 0.03% 2026-06-02
Gregory R Friberg
EVP, Chief R&D Officer · +45,600 options
Insider 47,732 0.02% 2026-09-30
Willard H Dere
Director
Insider 46,440 0.02% 2026-06-02
Cristin Hubbard
EVP, Chief Commercial Officer · +36,680 options
Insider 42,472 0.02% 2026-05-20
Elizabeth M Anderson
Director
Insider 41,940 0.02% 2026-06-02

Share count 193,694,734 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BMRN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMRN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.